• No results found

[PDF] Top 20 Analysis of pramipexole dose–response relationships in Parkinson's disease

Has 10000 "Analysis of pramipexole dose–response relationships in Parkinson's disease" found on our website. Below are the top 20 most common "Analysis of pramipexole dose–response relationships in Parkinson's disease".

Analysis of pramipexole dose–response relationships in Parkinson's disease

Analysis of pramipexole dose–response relationships in Parkinson's disease

... maintenance dose, PD stage, combined levodopa dose, and baseline tremor ...Parkinson’s Disease Rating Scale (UPDRS II+III) was used as a covariate for final score ... See full document

7

Nonergot dopamine-receptor agonists for treating Parkinson's disease – a network meta-analysis

Nonergot dopamine-receptor agonists for treating Parkinson's disease – a network meta-analysis

... age, disease duration, disease severity) (Supplementary ...Patients’ disease severity according to Hoehn and Yahr staging generally fell at stages I or II, with only a minor proportion of patients ... See full document

10

Utility of tolcapone in fluctuating Parkinson's disease

Utility of tolcapone in fluctuating Parkinson's disease

... an analysis conducted of data collected from 2 groups of patients enrolled in parallel long-term tolerability and efficacy studies of tolcapone and entacapone (Factor et al ...this analysis, tolcapone was ... See full document

10

Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system

Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system

... observed 16 weeks after surgery, suggesting that they were still releasing dopamine in the surrounding striatal tissue. Although the residual content of dopamine in the implants was not determined, its possible presence ... See full document

13

Aberrantly expressed long noncoding RNAs and genes in Parkinson's disease

Aberrantly expressed long noncoding RNAs and genes in Parkinson's disease

... Materials and methods: Three patients with PD and three normal controls were enrolled in the present study from July 12, 2017, to August 29, 2017. RNA sequencing and bioinformatics analy- sis were performed to obtain ... See full document

11

Genetic basis of Parkinson's disease: inheritance, penetrance, and expression

Genetic basis of Parkinson's disease: inheritance, penetrance, and expression

... linkage analysis and genome-wide association studies, but also new methods, like meta-analysis of genome- wide association studies, gene–gene and gene–environment interaction studies, pathway ... See full document

14

Applications of yoga in Parkinson's disease: a systematic literature review

Applications of yoga in Parkinson's disease: a systematic literature review

... The search results revealed a total of 214 articles (Figure 1). After the duplicates were removed, the titles were screened for evidence of a yoga intervention in persons with PD. The available abstracts for 43 articles ... See full document

8

Pain management in patients with Parkinson's disease: challenges and solutions

Pain management in patients with Parkinson's disease: challenges and solutions

... enced pain that a patient feels extends over a continuum from no pain to an extreme intensity of pain. This range of perceived pain appears continuous for the patient. Pain does not appear as an ordinary scale with jumps ... See full document

11

Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease

Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease

... (CSF) analysis of amyloid beta peptide 1–42 (A β 42), tau and phosphorylated ...postmortem analysis of brain histopathology showing dif- fuse neuronal and synaptic loss with extracellular amyloid plaques of ... See full document

14

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

... receive pramipexole ER (0.26–3.15 [0.375–4.5] mg qd), pramipexole IR ...primary analysis. At 18 weeks an interim analysis on a subset of 253 patients was planned to evaluate superiority of ... See full document

6

Animal models of Parkinson's disease and their applications

Animal models of Parkinson's disease and their applications

... it has been demonstrated that ( − )-sesamin from Asiasarum heterotropoides F. Maekawa var. mandshuricum, and GPS and the ethanol extract from G. pentaphyllum have neuroprotective effects on the l -DOPA-induced memory ... See full document

10

Investigational agents in the treatment of Parkinson's disease: focus on safinamide

Investigational agents in the treatment of Parkinson's disease: focus on safinamide

... Parkinson’s disease (PD) and provide an overview of the current pharmacological management strategies, with a specific focus on ...Parkinson’s Disease Rating Scale motor ...amide dose of 70 mg/day ... See full document

6

Dementia in Parkinson’s disease – a comprehensive review

Dementia in Parkinson’s disease – a comprehensive review

... An early symptom for dementia is usually mild forgetfulness which later advances into other cognitive abilities and memory to an extent where the patient is no longer capable of being independent. 12 14 Common symptoms ... See full document

5

Sleep disturbances in Parkinson's disease patients and management options

Sleep disturbances in Parkinson's disease patients and management options

... notes regarding clonazepam. First, in patients with gait insta- bility, clonazepam can cause greater gait instability at night. Patients note this problem especially when they have to use the bathroom at night, and must ... See full document

9

Review: management of Parkinson's disease

Review: management of Parkinson's disease

... Parkinson’s disease (PD) is one of the most frequent neurological ...the disease management often complicated even when the presence of PD seems ...the disease, especially with the progressive effect ... See full document

20

Pisa syndrome in Parkinson's disease: diagnostic and management challenges

Pisa syndrome in Parkinson's disease: diagnostic and management challenges

... neurodegenerative disease such as Parkinson’s disease, multiple system atrophy, and Alzheimer’s ...Parkinson’s disease, and provide an update on prevalence, pathophysiology, clinical manifestation, ... See full document

7

Dance therapy for individuals with Parkinson's disease: improving quality of life

Dance therapy for individuals with Parkinson's disease: improving quality of life

... supportive relationships between those with PD, their caregivers, and other loved ones; and 3) dance is enjoyable and motivating, possibly promoting long-term, consistent ... See full document

9

Potential sources of stem cells as a regenerative therapy for Parkinson's disease

Potential sources of stem cells as a regenerative therapy for Parkinson's disease

... point to the likelihood of synergistic interactions between endogenous and exogenous NSCs after transplantation. They reported that endogenous NSCs proximal to the graft expressed SHH, which possibly contributed to the ... See full document

9

Managing fatigue in patients with Parkinson's disease: a patient-focused perspective

Managing fatigue in patients with Parkinson's disease: a patient-focused perspective

... Parkinson’s disease and there is limited evidence regarding treatment of this ...Parkinson’s disease, including symptoms, epidemiology, diagnosis, and treatment, with a focus on the patient’s ... See full document

8

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole

... drug (eg, efficacy for symptomatic control of parkinsonism/ prevention of motor complications, safety, practicality, costs), to the patient (eg, symptoms, age, needs, expec- tations, experience, comorbidity, ... See full document

6

Show all 10000 documents...